Psychiatr Serv 52:1245-1247, September 2001
© 2001 American Psychiatric Association
Lessons Learned From Trends in Psychotropic Drug Expenditures in a Canadian Province
Carolyn S. Dewa, M.P.H., Ph.D. and
Paula Goering, R.N., Ph.D.
Although prescription drug prices are lower in Canada than in the United States, trends indicate that there has nevertheless been a steep increase in expenditures on psychotropic drugs. Between 1992 and 1998, such expenditures increased by 216 percent; 61 percent of these expenditures were on antidepressants, 33 percent on antipsychotics, and less than 7 percent on anxiolytics. Most of the increase in costs in Canada is attributable to a greater use of newer agents and the higher prices of these agents. These trends are a reminder not only that the use of newer, more expensive psychotherapeutic agents has become a widely embraced part of care but also that lower drug prices do not necessarily insulate a health care system from rising expenditures. The authors' findings prompt the questions of whether the use of these newer agents meets practice guidelines and whether there are ways to control the increases in drug expenditures while ensuring high-quality care.
This article has been cited by other articles:
|
|
|
|
 
C. S. Dewa, J. S. Hoch, P. Goering, E. Lin, and M. Paterson
Use of Antidepressants Among Canadian Workers Receiving Depression-Related Short-Term Disability Benefits
Psychiatr Serv,
May 1, 2003;
54(5):
724 - 729.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
